Login Register Cart 0
Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Current Status of and Perspectives on Radiolabelled Ubiquicidin 29-41 Derivatives for Bacterial Infection Imaging

Author(s): Yuhao Jiang and Junbo Zhang*

Volume 23, Issue 15, 2023

Published on: 15 February, 2023

Page: [1500 - 1506] Pages: 7

DOI: 10.2174/1389557523666230131100654

« Previous Next »
Graphical Abstract

[1]
Jain, S.K. The promise of molecular imaging in the study and treatment of infectious diseases. Mol. Imaging Biol., 2017, 19(3), 341-347.
[http://dx.doi.org/10.1007/s11307-017-1055-0] [PMID: 28155078]
[2]
Dutta, J.; Naicker, T.; Ebenhan, T.; Kruger, H.G.; Arvidsson, P.I.; Govender, T. Synthetic approaches to radiochemical probes for imaging of bacterial infections. Eur. J. Med. Chem., 2017, 133, 287-308.
[http://dx.doi.org/10.1016/j.ejmech.2017.03.060] [PMID: 28395216]
[3]
Li, S.; Wang, Y.; Xue, Z.; Jia, Y.; Li, R.; He, C.; Chen, H. The structure-mechanism relationship and mode of actions of antimicrobial peptides: A review. Trends Food Sci. Technol., 2021, 109, 103-115.
[http://dx.doi.org/10.1016/j.tifs.2021.01.005]
[4]
Yan, Y.; Li, Y.; Zhang, Z.; Wang, X.; Niu, Y.; Zhang, S.; Xu, W.; Ren, C. Advances of peptides for antibacterial applications. Colloids Surf. B Biointerfaces, 2021, 202, 111682.
[http://dx.doi.org/10.1016/j.colsurfb.2021.111682] [PMID: 33714188]
[5]
Lupetti, A.; Welling, M.M.; Pauwels, E.K.J.; Nibbering, P.H. Radiolabelled antimicrobial peptides for infection detection. Lancet Infect. Dis., 2003, 3(4), 223-229.
[http://dx.doi.org/10.1016/S1473-3099(03)00579-6] [PMID: 12679265]
[6]
Welling, M.M.; Paulusma-Annema, A.; Balter, H.S.; Pauwels, E.K.J.; Nibbering, P.H. Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations. Eur. J. Nucl. Med. Mol. Imaging, 2000, 27(3), 292-301.
[http://dx.doi.org/10.1007/s002590050036] [PMID: 10774881]
[7]
Welling, M.M.; Mongera, S.; Lupetti, A.; Balter, H.S.; Bonetto, V.; Mazzi, U.; Pauwels, E.K.J.; Nibbering, P.H. Radiochemical and biological characteristics of 99mTc-UBI 29–41 for imaging of bacterial infections. Nucl. Med. Biol., 2002, 29(4), 413-422.
[http://dx.doi.org/10.1016/S0969-8051(02)00292-5] [PMID: 12031876]
[8]
Ferro-Flores, G.; Arteaga de Murphy, C.; Pedraza-López, M.; Meléndez-Alafort, L.; Zhang, Y.M.; Rusckowski, M.; Hnatowich, D.J. In vitro and in vivo assessment of 99mTc-UBI specificity for bacteria. Nucl. Med. Biol., 2003, 30(6), 597-603.
[http://dx.doi.org/10.1016/S0969-8051(03)00054-4] [PMID: 12900285]
[9]
Welling, M.M.; Lupetti, A.; Balter, H.S.; Lanzzeri, S.; Souto, B.; Rey, A.M.; Savio, E.O.; Paulusma-Annema, A.; Pauwels, E.K.; Nibbering, P.H. 99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections. J. Nucl. Med., 2001, 42(5), 788-794.
[PMID: 11337578]
[10]
Akhtar, M.S.; Iqbal, J.; Khan, M.A.; Irfanullah, J.; Jehangir, M.; Khan, B.; Ul-Haq, I.; Muhammad, G.; Nadeem, M.A.; Afzal, M.S.; Imran, M.B. 99mTc-labeled antimicrobial peptide ubiquicidin (29-41) accumulates less in Escherichia coli infection than in Staphlococcus aureus infection. J. Nucl. Med., 2004, 45(5), 849-856.
[PMID: 15136636]
[11]
Doroudi, A.; Erfani, M.; Kamali, K.D.; Saadati, S.M.; Ahmadi, F.; Kiasat, A.; Khodayar, M.J.; Meghdadi, H. Sensitivity and specificity of 99mTc-UBI29-41 and 67Ga-Citrate scintigraphy imaging to discriminate infection lesion induced by Staphylococcus aureus and sterile inflammation lesion induced by Carrageenan in foot’s rat. IOSR J. Pharm., 2014, 4(11), 37-43.
[http://dx.doi.org/10.9790/3013-04011037043]
[12]
Sarda-Mantel, L.; Saleh-Mghir, A.; Welling, M.M.; Meulemans, A.; Vrigneaud, J.M.; Raguin, O.; Hervatin, F.; Martet, G.; Chau, F.; Lebtahi, R.; Le Guludec, D. Evaluation of 99mTc-UBI 29-41 scintigraphy for specific detection of experimental Staphylococcus aureus prosthetic joint infections. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34(8), 1302-1309.
[http://dx.doi.org/10.1007/s00259-007-0368-7] [PMID: 17334764]
[13]
Brouwer, C.P.; Gemmel, F.F.; Welling, M.M. Evaluation of 99mTc-UBI 29-41 scintigraphy for specific detection of experimental multidrug-resistant Staphylococcus aureus bacterial endocarditis. Q. J. Nucl. Med. Mol. Imaging, 2010, 54(4), 442-450.
[PMID: 20823811]
[14]
Nibbering, P.H.; Welling, M.M.; Paulusma-Annema, A.; Brouwer, C.P.J.M.; Lupetti, A.; Pauwels, E.K.J. 99mTc-Labeled UBI 29-41 peptide for monitoring the efficacy of antibacterial agents in mice infected with Staphylococcus aureus. J. Nucl. Med., 2004, 45(2), 321-326.
[PMID: 14960656]
[15]
Vallejo, E.; Martinez, I.; Tejero, A.; Hernandez, S.; Jimenez, L.; Bialostozky, D.; Sanchez, G.; Ilarraza, H.; Ferro-Flores, G. Clinical utility of 99mTc-labeled ubiquicidin 29-41 antimicrobial peptide for the scintigraphic detection of mediastinitis after cardiac surgery. Arch. Med. Res., 2008, 39(8), 768-774.
[http://dx.doi.org/10.1016/j.arcmed.2008.09.002] [PMID: 18996290]
[16]
Sepúlveda-Méndez, J.; de Murphy, C.A.; Rojas-Bautista, J.C.; Pedraza-López, M. Specificity of 99mTc-UBI for detecting infection foci in patients with fever in study. Nucl. Med. Commun., 2010, 31(10), 889-895.
[http://dx.doi.org/10.1097/MNM.0b013e32833d96d1] [PMID: 20683364]
[17]
Nazari, B.; Azizmohammadi, Z.; Rajaei, M.; Karami, M.; Javadi, H.; Assadi, M.; Asli, I.N. Role of 99mTc-ubiquicidin 29–41 scintigraphy to monitor antibiotic therapy in patients with orthopedic infection. Nucl. Med. Commun., 2011, 32(8), 745-751.
[http://dx.doi.org/10.1097/MNM.0b013e3283483964] [PMID: 21659909]
[18]
Saeed, S.; Zafar, J.; Khan, B.; Akhtar, A.; Qurieshi, S.; Fatima, S.; Ahmad, N.; Irfanullah, J. Utility of 99mTc-labelled antimicrobial peptide ubiquicidin (29-41) in the diagnosis of diabetic foot infection. Eur. J. Nucl. Med. Mol. Imaging, 2013, 40(5), 737-743.
[http://dx.doi.org/10.1007/s00259-012-2327-1] [PMID: 23361858]
[19]
Beiki, D.; Yousefi, G.; Fallahi, B.; Tahmasebi, M.N.; Gholamrezanezhad, A.; Fard-Esfahani, A.; Erfani, M.; Eftekhari, M. (99m)Tc-Ubiquicidin [29-41], a promising radiopharmaceutical to differentiate orthopedic implant infections from sterile inflammation. Iran. J. Pharm. Res., 2013, 12(2), 347-353.
[PMID: 24250609]
[20]
Shinto, A.S.; Mukherjee, A.; Karuppusamy, K.K.; Joseph, J.; Bhatt, J.; Korde, A.; Upadhya, I.; Arjun, C.; Samuel, G.; Dash, A. Clinical utility of 99mTc-ubiquicidin (29–41) as an adjunct to bone scan in differentiating infected versus noninfected loosening of prosthesis before revision surgery. Nucl. Med. Commun., 2017, 38(4), 285-290.
[http://dx.doi.org/10.1097/MNM.0000000000000648] [PMID: 28244975]
[21]
Sathekge, M.; Garcia-Perez, O.; Paez, D.; El-Haj, N.; Kain-Godoy, T.; Lawal, I.; Estrada-Lobato, E. Molecular imaging in musculoskeletal infections with 99mTc-UBI 29-41 SPECT/CT. Ann. Nucl. Med., 2018, 32(1), 54-59.
[http://dx.doi.org/10.1007/s12149-017-1219-7] [PMID: 29164482]
[22]
Ferro-Flores, G.; Arteaga de Murphy, C.; Palomares-Rodríguez, P.; Meléndez-Alafort, L.; Pedraza-López, M. Kit for instant 99mTc labeling of the antimicrobial peptide ubiquicidin 29-41. J. Radioanal. Nucl. Chem., 2005, 266(2), 307-311.
[http://dx.doi.org/10.1007/s10967-005-0908-1]
[23]
Arjun, C.; Mukherjee, A.; Bhatt, J.; Chaudhari, P.; Repaka, K.M.; Venkatesh, M.; Samuel, G. Studies on batch formulation of a kit for the preparation of the 99m Tc-Ubiquicidin (29-41): An infection imaging agent. Appl. Radiat. Isot., 2016, 107, 8-12.
[http://dx.doi.org/10.1016/j.apradiso.2015.09.009] [PMID: 26405838]
[24]
Bhatt Mitra, J.; Chatterjee, S.; Kumar, A.; Bandyopadhyay, A.; Mukherjee, A. Integrating a covalent probe with ubiquicidin fragment enables effective bacterial infection imaging. RSC Med. Chem., 2022, 13(10), 1239-1245.
[http://dx.doi.org/10.1039/D2MD00190J] [PMID: 36325398]
[25]
Welling, M.M.; Visentin, R.; Feitsma, H.I.J.; Lupetti, A.; Pauwels, E.K.J.; Nibbering, P.H. Infection detection in mice using 99mTc-labeled HYNIC and N2S2 chelate conjugated to the antimicrobial peptide UBI 29-41. Nucl. Med. Biol., 2004, 31(4), 503-509.
[http://dx.doi.org/10.1016/j.nucmedbio.2003.11.009] [PMID: 15093821]
[26]
Welling, M.M.; Korsak, A.; Gorska, B.; Oliver, P.; Mikolajczak, R.; Balter, H.S.; Feitsma, H.I.J.; Pauwels, E.K.J. Kit with technetium-99m labelled antimicrobial peptide UBI 29-41 for specific infection detection. J. Labelled Comp. Radiopharm., 2005, 48(9), 683-691.
[http://dx.doi.org/10.1002/jlcr.961]
[27]
Gandomkar, M.; Najafi, R.; Mazidi, M.; Goudarzi, M.; Mirfallah, S.H. New peptide based freeze-dried Kit [99mTc-HYNIC]-UBI 29-41 as a human specific infection imaging agent. Iran. J. Nucl. Med., 2008, 16(29), 25-30.
[28]
Meléndez-Alafort, L.; Nadali, A.; Pasut, G.; Zangoni, E.; De Caro, R.; Cariolato, L.; Giron, M.C.; Castagliuolo, I.; Veronese, F.M.; Mazzi, U. Detection of sites of infection in mice using 99mTc-labeled PN2S-PEG conjugated to UBI and 99mTc-UBI: A comparative biodistribution study. Nucl. Med. Biol., 2009, 36(1), 57-64.
[http://dx.doi.org/10.1016/j.nucmedbio.2008.10.011] [PMID: 19181269]
[29]
Ebenhan, T.; Chadwick, N.; Sathekge, M.M.; Govender, P.; Govender, T.; Kruger, H.G.; Marjanovic-Painter, B.; Zeevaart, J.R. Peptide synthesis, characterization and 68Ga-radiolabeling of NOTA-conjugated ubiquicidin fragments for prospective infection imaging with PET/CT. Nucl. Med. Biol., 2014, 41(5), 390-400.
[http://dx.doi.org/10.1016/j.nucmedbio.2014.02.001] [PMID: 24630816]
[30]
Ebenhan, T.; Zeevaart, J.R.; Venter, J.D.; Govender, T.; Kruger, G.H.; Jarvis, N.V.; Sathekge, M.M. Preclinical evaluation of 68Ga-labeled 1,4,7-triazacyclononane-1,4,7-triacetic acid-ubiquicidin as a radioligand for PET infection imaging. J. Nucl. Med., 2014, 55(2), 308-314.
[http://dx.doi.org/10.2967/jnumed.113.128397] [PMID: 24434293]
[31]
Vilche, M.; Reyes, A.L.; Vasilskis, E.; Oliver, P.; Balter, H.; Engler, H. 68 Ga-NOTA-UBI-29-41 as a PET tracer for detection of bacterial infection. J. Nucl. Med., 2016, 57(4), 622-627.
[http://dx.doi.org/10.2967/jnumed.115.161265] [PMID: 26769861]
[32]
Mukherjee, A.; Bhatt, J.; Shinto, A.; Korde, A.; Kumar, M.; Kamaleshwaran, K.; Joseph, J.; Sarma, H.D.; Dash, A. 68Ga-NOTA-ubiquicidin fragment for PET imaging of infection: From bench to bedside. J. Pharm. Biomed. Anal., 2018, 159, 245-251.
[http://dx.doi.org/10.1016/j.jpba.2018.06.064] [PMID: 29990892]
[33]
le Roux, J.; Rubow, S.; Ebenhan, T.; Wagener, C. An automated synthesis method for 68Ga-labelled ubiquicidin 29–41. J. Radioanal. Nucl. Chem., 2020, 323(1), 105-116.
[http://dx.doi.org/10.1007/s10967-019-06910-1]
[34]
Bhatt, J.; Mukherjee, A.; Korde, A.; Kumar, M.; Sarma, H.D.; Dash, A. Radiolabeling and preliminary evaluation of Ga-68 labeled nodaga-ubiquicidin fragments for prospective infection imaging. Mol. Imaging Biol., 2017, 19(1), 59-67.
[http://dx.doi.org/10.1007/s11307-016-0983-4] [PMID: 27406090]
[35]
Sasikumar, A.; Joy, A.; Nanabala, R.; Pillai, M.R.A. T A, H. 68Ga-DOTA ubiquicidin PET/CT in an infected implant. Clin. Nucl. Med., 2017, 42(2), e115-e116.
[http://dx.doi.org/10.1097/RLU.0000000000001464] [PMID: 27997417]
[36]
Sriwiang, W.; Rangsawai, W.; Pumkhem, S. 68 Ga-labeled ubiquicidin for monitoring of mouse infected with Staphylococcus aureus. J. Phys. Conf. Ser., 2019, 1285(1), 012028.
[http://dx.doi.org/10.1088/1742-6596/1285/1/012028]
[37]
Boddeti, D.K.; Kumar, V. Evaluation of 68Ga-DOTA-Ubiquicidin (29–41) for imaging Staphylococcus aureus (Staph A) infection and turpentine-induced inflammation in a preclinical setting. World J. Nucl. Med., 2021, 20(3), 266-272.
[http://dx.doi.org/10.4103/wjnm.WJNM_103_20] [PMID: 34703395]
[38]
Hsieh, W.; Ali, M.; Smyth, D.; Tsopelas, C. Radiosynthesis and quality control of 68Ga-DFO-UBI 29-41. Intern. Med. J., 2015, 45(S1), 33-33.
[39]
Zijlstra, S.; Gunawan, J.; Freytag, C.; Burchert, W. Synthesis and evaluation of fluorine-18 labelled compounds for imaging of bacterial infections with pet. Appl. Radiat. Isot., 2006, 64(7), 802-807.
[http://dx.doi.org/10.1016/j.apradiso.2006.02.095] [PMID: 16617022]
[40]
Holik, H.A.; Ibrahim, F.M.; Elaine, A.A.; Putra, B.D.; Achmad, A.; Kartamihardja, A.H.S. The chemical scaffold of theranostic radiopharmaceuticals: Radionuclide, bifunctional chelator, and pharmacokinetics modifying linker. Molecules, 2022, 27(10), 3062.
[http://dx.doi.org/10.3390/molecules27103062] [PMID: 35630536]
[41]
Wagner, L.; Kenzhebayeva, B.; Dhaini, B.; Boukhlef, S.; Moussaron, A.; Mordon, S.; Frochot, C.; Collet, C.; Acherar, S. Folate-based radiotracers for nuclear imaging and radionuclide therapy. Coord. Chem. Rev., 2022, 470, 214702.
[http://dx.doi.org/10.1016/j.ccr.2022.214702]
[42]
Fersing, C.; Masurier, N.; Rubira, L.; Deshayes, E.; Lisowski, V. AAZTA-derived chelators for the design of innovative radiopharmaceuticals with theranostic applications. Pharmaceuticals, 2022, 15(2), 234.
[http://dx.doi.org/10.3390/ph15020234] [PMID: 35215346]
[43]
Backhaus, P.; Gierse, F.; Burg, M.C.; Büther, F.; Asmus, I.; Dorten, P.; Cufe, J.; Roll, W.; Neri, D.; Cazzamalli, S.; Millul, J.; Mock, J.; Galbiati, A.; Zana, A.; Schäfers, K.P.; Hermann, S.; Weckesser, M.; Tio, J.; Wagner, S.; Breyholz, H.J.; Schäfers, M. Translational imaging of the Fibroblast Activation Protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA. Eur. J. Nucl. Med. Mol. Imaging, 2022, 49(6), 1822-1832.
[http://dx.doi.org/10.1007/s00259-021-05653-0] [PMID: 34957527]
[44]
Zha, Z.; Wu, Z.; Choi, S.R.; Ploessl, K.; Smith, M.; Alexoff, D.; Zhu, L.; Kung, H.F. A new [68Ga]Ga-HBED-CC-bisphosphonate as a bone imaging agent. Mol. Pharm., 2020, 17(5), 1674-1684.
[http://dx.doi.org/10.1021/acs.molpharmaceut.0c00103] [PMID: 32251600]
[45]
Wang, L.; Shi, J.; Kim, Y.S.; Zhai, S.; Jia, B.; Zhao, H.; Liu, Z.; Wang, F.; Chen, X.; Liu, S. Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers. Mol. Pharm., 2009, 6(1), 231-245.
[http://dx.doi.org/10.1021/mp800150r] [PMID: 19067525]
[46]
Zhao, L.; Chen, J.; Pang, Y.; Fang, J.; Fu, K.; Meng, L.; Zhang, X.; Guo, Z.; Wu, H.; Sun, L.; Su, G.; Lin, Q.; Chen, H. Development of fibroblast activation protein inhibitor-based dimeric radiotracers with improved tumor retention and antitumor efficacy. Mol. Pharm., 2022, 19(10), 3640-3651.
[http://dx.doi.org/10.1021/acs.molpharmaceut.2c00424] [PMID: 35917335]

Rights & Permissions Print Cite
Article Metrics
23
2
© 2024 Bentham Science Publishers | Privacy Policy